Suriclone
| Suriclone | |
|---|---|
 | |
| Molecular structure via molpic based on CDK |
| Rotamer [] | |
|---|---|
| Conformer structure via 3Dmol.js |
| Physical properties [] | |
|---|---|
| Molecular mass | 478.0 g/mol [1] |
| Predicted LogP | 2.8 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C20H20ClN5O3S2 [1] |
| IUPAC name | [6-(7-chloro-1,8-naphthyridin-2-yl)-5-oxo-3,7-dihydro-2H-[1,4]dithiino[2,3-c]pyrrol-7-yl] 4-methylpiperazine-1-carboxylate [1] |
| SMILES | CN1CCN(CC1)C(=O)OC2C3=C(C(=O)N2C4=NC5=C(C=C4)C=CC(=N5)Cl)SCCS3 [1] |
| InChI | InChI=1S/C20H20ClN5O3S2/c1-24-6-8-25(9-7-24)20(28)29-19-16-15(30-10-11-31-16)18(27)26(19)14-5-3-12-2-4-13(21)22-17(12)23-14/h2-5,19H,6-11H2,1H3 [1] |
| InChIKey | RMXOUBDDDQUBKD-UHFFFAOYSA-N [1] |
Suriclone (also known as Suril, Suriclona, Celexane, Suriclonum, RP 31264, RP-31264, 4-Methyl-1-piperazinecarboxylic acid ester with (+-)-6-(7-chloro-1,8-naphthyridin-2-yl)-2,3,6,7-tetrahydro-7-hydroxy-5H-p-dithiino(2,3-c)pyrrol-5-one, (8-(7-chloro(1,8)naphthyridin-2-yl)-7-oxo-2,5-dithia-8-azabicyclo(4.3.0)non-10-en-9-yl) 4-methylpiperazine-1-carboxylate, Dtxcid70814651 or 6-(7-chloro-1,8-naphthyridin-2-yl)-2,3,6,7-tetrahydro-7-oxo-5H-(1,4)dithiino(2,3-c)pyrrol-5-yl-4-methylpiperazine-1-carboxylate) is a
Chemistry
Stereochemistry []
Suriclone is a racemic mixture of the enantiomers.
| Stereoisomerism |
|---|
| Stereoisomer enumberation with rdkit |
Druglikeness
Lipinski's rule of five
Suriclone matches Lipinski's rule of five.See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 40903, Suriclone. Accessed June 12, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/40903
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Suriclone. UNII: LNC9G689VR. Global Substance Registration System. Accessed June 12, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/LNC9G689VR